$EWW is probably a buy now
Cantor $CYTK see Afi’ as the clear class leader, offering the most complete efficacy/safety balance with a maturing global commercial infrastructure and label expansion strategies in motion. https://t.co/qyFyjXR4El
Cantor Bottom Line $EWTX EDG-7500 shows signs of activity, particularly in NT-proBNP&KCCQ, but small N, higher AF risk, lack of durability severely limit its competitive read-through.
Cytokinetics Inc. (CYTK) has experienced a notable decline in its stock value, dropping 62% since a confirmed buyout offer from the SEC fell through. The stock has lost 13% since the SEQUOIA event and has been cut in half over the past 15 months. Concerns have been raised regarding the company's management, with reports indicating that the CEO and other executives have not purchased shares, opting instead to exercise options and sell. Meanwhile, Edgewise Therapeutics Inc. (EWTX) announced positive top-line results from its Phase 2 CIRRUS-HCM trial of EDG-7500 for hypertrophic cardiomyopathy, although the stock is trading at a 25% discount to its recent $200 million underwritten offering. EWTX shares gapped down to $12 following adverse events reported on the same day as the offering priced at $20, reflecting volatility in the biotech sector. Analysts suggest that the data from EWTX may impact perceptions of CYTK's Aficamten, with some indicating that Aficamten remains the class leader in the market.
